Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of Physical Disability in Subjects With Multiple Sclerosis With Relapses
Brief Summary: The primary objective was to determine the effect of teriflunomide on the frequency of relapses in patients with relapsing multiple sclerosis (MS).

Secondary objectives were:

* to evaluate the effect of teriflunomide on the accumulation of disability as measured by Expanded Disability Status Scale \[EDSS\], the burden of disease as measured by Magnetic Resonance Imaging \[MRI\] and patient-reported fatigue;
* to evaluate the safety and tolerability of teriflunomide.


Options:
A: Arm Label: Teriflunomide 7 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for teriflunomide) | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Teriflunomide 14 mg, Teriflunomide 7 mg | Intervention Type: DRUG; Name: Placebo (for teriflunomide); Assigned to Arm(s): Placebo
B: Arm Label: Placebo + IFN-β; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for teriflunomide), Drug: Interferon-β [IFN-β] | Arm Label: Teriflunomide 7 mg + IFN-β; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide, Drug: Interferon-β [IFN-β] | Arm Label: Teriflunomide 14 mg + IFN-β; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide, Drug: Interferon-β [IFN-β] | Arm Label: Placebo + GA; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for teriflunomide), Drug: Glatiramer Acetate [GA] | Arm Label: Teriflunomide 7 mg + GA; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide, Drug: Glatiramer Acetate [GA] | Arm Label: Teriflunomide 14 mg + GA; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide, Drug: Glatiramer Acetate [GA] | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Teriflunomide 14 mg + GA, Teriflunomide 14 mg + IFN-β, Teriflunomide 7 mg + GA, Teriflunomide 7 mg + IFN-β | Intervention Type: DRUG; Name: Placebo (for teriflunomide); Assigned to Arm(s): Placebo + GA, Placebo + IFN-β | Intervention Type: DRUG; Name: Interferon-β [IFN-β]; Assigned to Arm(s): Placebo + IFN-β, Teriflunomide 14 mg + IFN-β, Teriflunomide 7 mg + IFN-β | Intervention Type: DRUG; Name: Glatiramer Acetate [GA]; Assigned to Arm(s): Placebo + GA, Teriflunomide 14 mg + GA, Teriflunomide 7 mg + GA
C: Arm Label: BIIB019; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab), Biological: trivalent seasonal influenza vaccine | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab); Assigned to Arm(s): BIIB019 | Intervention Type: BIOLOGICAL; Name: trivalent seasonal influenza vaccine; Assigned to Arm(s): BIIB019
D: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo / Teriflunomide 14 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Teriflunomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / Teriflunomide 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Placebo / Teriflunomide 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg

Answer: A